SELLAS Life Sciences Shares Drop After Analyst Downgrade

The biopharmaceutical company's stock fell after a 'sell' rating from Weiss Ratings.

Published on Feb. 14, 2026

Got story updates? Submit your updates here. ›

Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) dropped on Wednesday after the stock opened lower than its previous close of $3.76. The stock last traded at $3.62, with over 1 million shares changing hands. Weiss Ratings reiterated a 'sell (d-)' rating on SELLAS shares, contributing to the stock's decline.

Why it matters

SELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies. An analyst downgrade can significantly impact investor sentiment and the company's stock price, which is an important indicator of its financial health and ability to raise capital for further research and development.

The details

According to the report, SELLAS shares gapped down prior to the market open, with the stock opening at $3.61 compared to the previous close of $3.76. The stock last traded at $3.62, with a trading volume of over 1 million shares. Weiss Ratings reiterated a 'sell (d-)' rating on SELLAS shares, which likely contributed to the stock's decline.

  • The report was published on February 14, 2026.

The players

SELLAS Life Sciences Group, Inc.

A clinical-stage biopharmaceutical company focused on developing cancer immunotherapies, particularly targeting the Wilms' tumor 1 (WT1) antigen.

Weiss Ratings

A financial research and ratings firm that provides independent analysis and ratings on stocks, mutual funds, and other financial products.

Got photos? Submit your photos here. ›

The takeaway

The drop in SELLAS Life Sciences' stock price following the Weiss Ratings downgrade highlights the importance of analyst sentiment in the biopharmaceutical industry. Investors will be closely watching to see if the company can regain momentum and continue advancing its cancer immunotherapy pipeline.